Preclinical evidence toward the use of ketamine for recombinant tissue-type plasminogen activator-mediated thrombolysis under anesthesia or sedation.
Le 02 Nov 2021
Auteur : Gakuba C, Gauberti M, Mazighi M, Defer G, Hanouz JL, Vivien D
Année : 2011
Journal : Stroke 1524-4628
PubMed Id : 21817137
Endovascular treatment of ischemic stroke usually involves recombinant tissue-type plasminogen activator (rtPA)-mediated thrombolysis in anesthetized patients. Paradoxically, differential influences of anesthetic agents on thrombolysis outcome remain unknown.